Literature DB >> 27400264

International AIDS Society global scientific strategy: towards an HIV cure 2016.

Steven G Deeks1, Sharon R Lewin2,3, Anna Laura Ross4, Jintanat Ananworanich5,6, Monsef Benkirane7, Paula Cannon8, Nicolas Chomont9, Daniel Douek10, Jeffrey D Lifson11, Ying-Ru Lo12, Daniel Kuritzkes13, David Margolis14, John Mellors15, Deborah Persaud16, Joseph D Tucker17, Françoise Barre-Sinoussi18, Galit Alter19, Judith Auerbach1, Brigitte Autran20,21,22, Dan H Barouch23,19, Georg Behrens24, Marina Cavazzana25, Zhiwei Chen26, Éric A Cohen27, Giulio Maria Corbelli28, Serge Eholié29, Nir Eyal30, Sarah Fidler31, Laurindo Garcia32, Cynthia Grossman33, Gail Henderson14, Timothy J Henrich1,13, Richard Jefferys34, Hans-Peter Kiem35, Joseph McCune1, Keymanthri Moodley36, Peter A Newman37, Monique Nijhuis38, Moses Supercharger Nsubuga39, Melanie Ott40, Sarah Palmer41, Douglas Richman42, Asier Saez-Cirion18, Matthew Sharp43, Janet Siliciano44, Guido Silvestri45, Jerome Singh46, Bruno Spire47, Jeffrey Taylor48, Martin Tolstrup49, Susana Valente50, Jan van Lunzen51, Rochelle Walensky52, Ira Wilson53, Jerome Zack54.   

Abstract

Antiretroviral therapy is not curative. Given the challenges in providing lifelong therapy to a global population of more than 35 million people living with HIV, there is intense interest in developing a cure for HIV infection. The International AIDS Society convened a group of international experts to develop a scientific strategy for research towards an HIV cure. This Perspective summarizes the group's strategy.

Entities:  

Mesh：

Year:  2016        PMID： 27400264      PMCID： PMC5322797          DOI： 10.1038/nm.4108

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


  121 in total

1.  CTL fail to accumulate at sites of HIV-1 replication in lymphoid tissue.

Authors:  Elizabeth Connick; Teresa Mattila; Joy M Folkvord; Rick Schlichtemeier; Amie L Meditz; M Graham Ray; Martin D McCarter; Samantha Mawhinney; Aaron Hage; Cara White; Pamela J Skinner
Journal:  J Immunol       Date:  2007-06-01       Impact factor: 5.422

2.  OKT3 and IL-2 treatment for purging of the latent HIV-1 reservoir in vivo results in selective long-lasting CD4+ T cell depletion.

Authors:  R M van Praag; J M Prins; M T Roos; P T Schellekens; I J Ten Berge; S L Yong; H Schuitemaker; A J Eerenberg; S Jurriaans; F de Wolf; C H Fox; J Goudsmit; F Miedema; J M Lange
Journal:  J Clin Immunol       Date:  2001-05       Impact factor: 8.317

3.  Depletion of latent HIV-1 infection in vivo: a proof-of-concept study.

Authors:  Ginger Lehrman; Ian B Hogue; Sarah Palmer; Cheryl Jennings; Celsa A Spina; Ann Wiegand; Alan L Landay; Robert W Coombs; Douglas D Richman; John W Mellors; John M Coffin; Ronald J Bosch; David M Margolis
Journal:  Lancet       Date:  2005 Aug 13-19       Impact factor: 79.321

4.  HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects.

Authors:  Maria J Buzón; Marta Massanella; Josep M Llibre; Anna Esteve; Viktor Dahl; Maria C Puertas; Josep M Gatell; Pere Domingo; Roger Paredes; Mark Sharkey; Sarah Palmer; Mario Stevenson; Bonaventura Clotet; Julià Blanco; Javier Martinez-Picado
Journal:  Nat Med       Date:  2010-03-14       Impact factor: 53.440

5.  The human factors YY1 and LSF repress the human immunodeficiency virus type 1 long terminal repeat via recruitment of histone deacetylase 1.

Authors:  J J Coull; F Romerio; J M Sun; J L Volker; K M Galvin; J R Davie; Y Shi; U Hansen; D M Margolis
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

6.  Establishment of HIV latency in primary CD4+ cells is due to epigenetic transcriptional silencing and P-TEFb restriction.

Authors:  Mudit Tyagi; Richard John Pearson; Jonathan Karn
Journal:  J Virol       Date:  2010-04-21       Impact factor: 5.103

7.  Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation.

Authors:  Gero Hütter; Daniel Nowak; Maximilian Mossner; Susanne Ganepola; Arne Müssig; Kristina Allers; Thomas Schneider; Jörg Hofmann; Claudia Kücherer; Olga Blau; Igor W Blau; Wolf K Hofmann; Eckhard Thiel
Journal:  N Engl J Med       Date:  2009-02-12       Impact factor: 91.245

8.  Orientation-dependent regulation of integrated HIV-1 expression by host gene transcriptional readthrough.

Authors:  Yefei Han; Yijie B Lin; Wenfeng An; Jie Xu; Hung-Chih Yang; Karen O'Connell; Dominic Dordai; Jef D Boeke; Janet D Siliciano; Robert F Siliciano
Journal:  Cell Host Microbe       Date:  2008-08-14       Impact factor: 21.023

9.  HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation.

Authors:  Nicolas Chomont; Mohamed El-Far; Petronela Ancuta; Lydie Trautmann; Francesco A Procopio; Bader Yassine-Diab; Geneviève Boucher; Mohamed-Rachid Boulassel; Georges Ghattas; Jason M Brenchley; Timothy W Schacker; Brenna J Hill; Daniel C Douek; Jean-Pierre Routy; Elias K Haddad; Rafick-Pierre Sékaly
Journal:  Nat Med       Date:  2009-06-21       Impact factor: 53.440

10.  Dangerous medicines: unproven AIDS cures and counterfeit antiretroviral drugs.

Authors:  Joseph J Amon
Journal:  Global Health       Date:  2008-02-27       Impact factor: 4.185
View more
  221 in total

1.  Halogen Bond Interactions of Novel HIV-1 Protease Inhibitors (PI) (GRL-001-15 and GRL-003-15) with the Flap of Protease Are Critical for Their Potent Activity against Wild-Type HIV-1 and Multi-PI-Resistant Variants.

Authors:  Shin-Ichiro Hattori; Hironori Hayashi; Haydar Bulut; Kalapala Venkateswara Rao; Prasanth R Nyalapatla; Kazuya Hasegawa; Manabu Aoki; Arun K Ghosh; Hiroaki Mitsuya
Journal:  Antimicrob Agents Chemother       Date:  2019-05-24       Impact factor: 5.191

2.  Towards a cure for human immunodeficiency virus.

Authors:  Matthew C Pitman; Sharon R Lewin
Journal:  Intern Med J       Date:  2018-01       Impact factor: 2.048

3.  Establishment of a Novel Humanized Mouse Model To Investigate In Vivo Activation and Depletion of Patient-Derived HIV Latent Reservoirs.

Authors:  Nina C Flerin; Ariola Bardhi; Jian Hua Zheng; Maria Korom; Joy Folkvord; Colin Kovacs; Erika Benko; Ronald Truong; Talia Mota; Elizabeth Connick; R Brad Jones; Rebecca M Lynch; Harris Goldstein
Journal:  J Virol       Date:  2019-03-05       Impact factor: 5.103

4.  Transient loss of detectable HIV-1 RNA following brentuximab vedotin anti-CD30 therapy for Hodgkin lymphoma.

Authors:  Chia-Ching Wang; Cassandra Thanh; Erica A Gibson; Maya Ball-Burack; Louise E Hogan; Benjamin Descours; Norman Jones; Alexander B Carvidi; Sadie Munter; Sonia Bakkour; Michael P Busch; Jeffrey M Milush; Steven G Deeks; Timothy J Henrich
Journal:  Blood Adv       Date:  2018-12-11

Review 5.  Towards pathogen inactivation of red blood cells and whole blood targeting viral DNA/RNA: design, technologies, and future prospects for developing countries.

Authors:  Victor J Drew; Lassina Barro; Jerard Seghatchian; Thierry Burnouf
Journal:  Blood Transfus       Date:  2017-04-13       Impact factor: 3.443

6.  Impact of alemtuzumab on HIV persistence in an HIV-infected individual on antiretroviral therapy with Sezary syndrome.

Authors:  Thomas A Rasmussen; James McMahon; J Judy Chang; Jori Symons; Michael Roche; Ashanti Dantanarayana; Afam Okoye; Bonnie Hiener; Sarah Palmer; Wen Shi Lee; Stephen J Kent; Carrie Van Der Weyden; H Miles Prince; Paul U Cameron; Sharon R Lewin
Journal:  AIDS       Date:  2017-08-24       Impact factor: 4.177

7.  A humanized mouse-based HIV-1 viral outgrowth assay with higher sensitivity than in vitro qVOA in detecting latently infected cells from individuals on ART with undetectable viral loads.

Authors:  Paige Charlins; Kimberly Schmitt; Leila Remling-Mulder; Louise E Hogan; Emily Hanhauser; Kristen S Hobbs; Frederick Hecht; Steven G Deeks; Timothy J Henrich; Ramesh Akkina
Journal:  Virology       Date:  2017-04-19       Impact factor: 3.616

8.  Can research at the end of life be a useful tool to advance HIV cure?

Authors:  Sara Gianella; Jeff Taylor; Timothy R Brown; Andy Kaytes; Cristian L Achim; David J Moore; Susan J Little; Ronald J Ellis; Davey M Smith
Journal:  AIDS       Date:  2017-01-02       Impact factor: 4.177

9.  Cell-associated HIV-1 RNA predicts viral rebound and disease progression after discontinuation of temporary early ART.

Authors:  Alexander O Pasternak; Marlous L Grijsen; Ferdinand W Wit; Margreet Bakker; Suzanne Jurriaans; Jan M Prins; Ben Berkhout
Journal:  JCI Insight       Date:  2020-03-26

10.  The interferon paradox: can inhibiting an antiviral mechanism advance an HIV cure?

Authors:  Steven G Deeks; Pamela M Odorizzi; Rafick-Pierre Sekaly
Journal:  J Clin Invest       Date:  2016-12-12       Impact factor: 14.808
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.